Search

Your search keyword '"Caiaffa, Maria Filomena"' showing total 194 results
Start Over Author "Caiaffa, Maria Filomena"
194 results on '"Caiaffa, Maria Filomena"'

1. Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study

Author

Vultaggio, Alessandra, Aliani, Maria, Altieri, Elena, Bracciale, Pietro, Brussino, Luisa, Caiaffa, Maria Filomena, Cameli, Paolo, Canonica, Giorgio Walter, Caruso, Cristiano, Centanni, Stefano, D’Amato, Maria, De Michele, Fausto, Del Giacco, Stefano, Di Marco, Fabiano, Menzella, Francesco, Pelaia, Girolamo, Rogliani, Paola, Romagnoli, Micaela, Schino, Pietro, Senna, Gianenrico, Benci, Marco, Boarino, Silvia, and Schroeder, Jan Walter

Published
2023
Full Text
View/download PDF

2. Long-Term Clinical and Sustained REMIssion in Severe Eosinophilic Asthma Treated With Mepolizumab: The REMI-M Study

Author

Intravaia, Rossella, Porto, Morena, Impellizzeri, Pietro, Frazzetto, Valentina, Bonsignore, Martina, Giannì, Concetta, Nardo, Andrea Alessia, Vignera, Fabio, Busceti, Maria Teresa, Lombardo, Nicola, Lacedonia, Donato, Tondo, Pasquale, Soccio, Piera, Quarato, Carla Maria Irene, Montagnolo, Francesca, Salerno, Vittorio, Maselli, Leonardo, Julai, Ernesto, Coppa, Francesco, Grimaldi, Lucia, Carrieri, Isabella, Sola, Alessio, Balestrino, Marco, Mariniello, Domenica Francesca, Benfante, Alida, Spadaro, Giuseppe, Detoraki, Aikaterini, Ricciardi, Luisa, Antonio, Franzese, Valeria, Longobardi, Crimi, Claudia, Nolasco, Santi, Noto, Alberto, Maglio, Angelantonio, Quaranta, Vitaliano Nicola, Di Bona, Danilo, Scioscia, Giulia, Papia, Francesco, Caiaffa, Maria Filomena, Calabrese, Cecilia, D’Amato, Maria, Pelaia, Corrado, Campisi, Raffaele, Vitale, Carolina, Ciampo, Luigi, Dragonieri, Silvano, Minenna, Elena, Massaro, Federica, Gallotti, Lorena, Macchia, Luigi, Triggiani, Massimo, Scichilone, Nicola, Valenti, Giuseppe, Pelaia, Girolamo, Foschino Barbaro, Maria Pia, Carpagnano, Giovanna Elisiana, Vatrella, Alessandro, and Crimi, Nunzio

Published
2024
Full Text
View/download PDF

3. Severe Asthma Network Italy Definition of Clinical Remission in Severe Asthma: A Delphi Consensus

Author

Canonica, Giorgio Walter, Blasi, Francesco, Carpagnano, Giovanna Elisiana, Guida, Giuseppe, Heffler, Enrico, Paggiaro, Pierluigi, Allegrini, Chiara, Antonelli, Andrea, Aruanno, Arianna, Bacci, Elena, Bagnasco, Diego, Beghè, Bianca, Bonavia, Marco, Bonini, Matteo, Brussino, Luisa, Caiaffa, Maria Filomena, Calabrese, Cecilia, Camiciottoli, Gianna, Caminati, Marco, Caruso, Cristiano, Cavallini, Mirta, Chieco Bianchi, Fulvia, Conte, Maria Elisabetta, Corsico, Angelo Guido, Cosmi, Lorenzo, Costantino, Mariateresa, Costanzo, Giulia, Crivellaro, Mariaangiola, D'Alò, Simona, D'Amato, Mariella, Detoraki, Aikaterini, Di Proietto, Maria Carmela, Facciolongo, Nicola Cosimo, Ferri, Sebastian, Fierro, Vincenzo, Foschino, Maria Pia, Latorre, Manuela, Lombardi, Carlo, Macchia, Luigi, Milanese, Manlio, Montagni, Marcello, Parazzini, Elena Maria, Parente, Roberta, Passalacqua, Giovanni, Patella, Vincenzo, Pelaia, Girolamo, Pini, Laura, Puggioni, Francesca, Ricciardi, Luisa, Ridolo, Erminia, Rolo, Joyce, Scichilone, Nicola, Scioscia, Giulia, Senna, Gianenrico, Solidoro, Paolo, Varricchi, Gilda, Vianello, Andrea, Yacoub, Mona Rita, and Yang, Baoran

Published
2023
Full Text
View/download PDF

4. ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study

Author

Menzella, Francesco, Bargagli, Elena, Aliani, Maria, Bracciale, Pietro, Brussino, Luisa, Caiaffa, Maria Filomena, Caruso, Cristiano, Centanni, Stefano, D’Amato, Maria, Del Giacco, Stefano, De Michele, Fausto, Di Marco, Fabiano, Pastorello, Elide Anna, Pelaia, Girolamo, Rogliani, Paola, Romagnoli, Micaela, Schino, Pietro, Senna, Gianenrico, Vultaggio, Alessandra, Simoni, Lucia, Ori, Alessandra, Boarino, Silvia, Vitiello, Gianfranco, Altieri, Elena, and Canonica, Giorgio Walter

Published
2022
Full Text
View/download PDF

6. Benralizumab Effectiveness in Severe Eosinophilic Asthma with and without Chronic Rhinosinusitis with Nasal Polyps: A Real-World Multicenter Study

Author

Nolasco, Santi, Crimi, Claudia, Pelaia, Corrado, Benfante, Alida, Caiaffa, Maria Filomena, Calabrese, Cecilia, Carpagnano, Giovanna Elisiana, Ciotta, Domenico, D'Amato, Maria, Macchia, Luigi, Pelaia, Girolamo, Pellegrino, Simona, Scichilone, Nicola, Scioscia, Giulia, Spadaro, Giuseppe, Campisi, Raffaele, Valenti, Giuseppe, Vatrella, Alessandro, and Crimi, Nunzio

Published
2021
Full Text
View/download PDF

7. Long-Term Clinical and Sustained REMIssion in Severe Eosinophilic Asthma treated with Mepolizumab: The REMI-M study

Author

Crimi, Claudia, primary, Nolasco, Santi, additional, Noto, Alberto, additional, Maglio, Angelantonio, additional, Quaranta, Vitaliano Nicola, additional, Di Bona, Danilo, additional, Scioscia, Giulia, additional, Papia, Francesco, additional, Caiaffa, Maria Filomena, additional, Calabrese, Cecilia, additional, D’Amato, Maria, additional, Pelaia, Corrado, additional, Campisi, Raffaele, additional, Vitale, Carolina, additional, Ciampo, Luigi, additional, Dragonieri, Silvano, additional, Minenna, Elena, additional, Massaro, Federica, additional, Gallotti, Lorena, additional, Macchia, Luigi, additional, Triggiani, Massimo, additional, Scichilone, Nicola, additional, Valenti, Giuseppe, additional, Pelaia, Girolamo, additional, Barbaro, Maria Pia Foschino, additional, Carpagnano, Giovanna Elisiana, additional, Vatrella, Alessandro, additional, and Crimi, Nunzio, additional

Published
2024
Full Text
View/download PDF

8. Sustained Effectiveness of Benralizumab in Naïve and Biologics-Experienced Severe Eosinophilic Asthma Patients: Results from the ANANKE Study

Author

Cameli, Paolo, primary, Aliani, Maria, additional, Altieri, Elena, additional, Bracciale, Pietro, additional, Brussino, Luisa, additional, Caiaffa, Maria Filomena, additional, Canonica, Giorgio, additional, Caruso, Cristiano, additional, Centanni, Stefano, additional, D'Amato, Maria, additional, De Michele, Fausto, additional, Del Giacco, Stefano, additional, Di Marco, Fabiano, additional, Pelaia, Girolamo, additional, Rogliani, Paola, additional, Romagnoli, Micaela, additional, Schino, Pietro, additional, Schroeder, Jan Walter, additional, Senna, Gianenrico, additional, Vultaggio, Alessandra, additional, Benci, Marco, additional, Boarino, Silvia, additional, and Menzella, Francesco, additional

Published
2024
Full Text
View/download PDF

9. Severe asthma: One disease and multiple definitions

Author

Guarnieri, Gabriella, Patella, Vincenzo, Maria Pia, Foschino Barbaro, Carpagnano, Giovanna Elisiana, Colle, Anna del, Scioscia, Giulia, Gerolamo, Pelaia, Puggioni, Francesca, Racca, Francesca, Favero, Elisabetta, Iannacone, Sandra, Savi, Eleonora, Montagni, Marcello, Camiciottoli, Gianna, Allegrini, Chiara, Lombardi, Carlo, Spadaro, Giuseppe, Detoraki, Caterina, Menzella, Francesco, Galeone, Carla, Ruggiero, Patrizia, Yacoub, Monna Rita, Berti, Alvise, Scichilone, Nicola, Durante, Carmen, Costantino, Maria Teresa, Roncallo, Chiara, Braschi, Mariachiara, D’Adda, Alice, Ridolo, Erminia, Triggiani, Massimo, Parente, Roberta, Maria, D’Amato, Verrillo, Maria Vittoria, Rolla, Giovanni, Brussino, Luisa, Frazzetto, Agata Valentina, Cristina, Zappa Maria, Lilli, Marianna, Crimi, Nunzio, Bonavia, Marco, Corsico, Angelo Guido, Grosso, Amelia, Del Giacco, Stefano, Deidda, Margherita, Ricciardi, Luisa, Isola, Stefania, Cicero, Francesca, Amato, Giuliana, Vita, Federica, Spanevello, Antonio, Pignatti, Patrizia, Cherubino, Francesca, Visca, Dina, Massimo Ricciardolo, Fabio Luigi, Anna Carriero, Vitina Maria, Bertolini, Francesca, Santus, Pierachille, Barlassina, Roberta, Airoldi, Andrea, Guida, Giuseppe, Eleonora, Nucera, Aruanno, Arianna, Rizzi, Angela, Caruso, Cristiano, Colantuono, Stefania, Senna, Gianenrico, Caminati, Marco, Arcolaci, Alessandra, Vianello, Andrea, Bianchi, Fulvia Chieco, Marchi, Maria Rita, Centanni, Stefano, Luraschi, Simone, Ruggeri, Silvia, Rinaldo, Rocco, Parazzini, Elena, Calabrese, Cecilia, Flora, Martina, Cosmi, Lorenzo, Di Pietro, Linda, Maggi, Enrico, Pini, Laura, Macchia, Luigi, Di Bona, Danilo, Richeldi, Luca, Condoluci, Carola, Fuso, Leonello, Bonini, Matteo, Farsi, Alessandro, Carli, Giulia, Montuschi, Paolo, Santini, Giuseppe, Conte, Maria Elisabetta, Turchet, Elisa, Barbetta, Carlo, Mazza, Francesco, D’Alo, Simona, Pucci, Stefano, Caiaffa, Maria Filomena, Minenna, Elena, D'Elia, Luciana, Pasculli, Carlo, Viviano, Vittorio, Tarsia, Paolo, Rolo, Joyce, Di Proietto, Mariacarmela, Lo Cicero, Salvatore, Bagnasco, Diego, Paggiaro, Pierluigi, Latorre, Manuela, Folli, Chiara, Testino, Elisa, Bassi, Arianna, Milanese, Manlio, Heffler, Enrico, Manfredi, Andrea, Riccio, Anna Maria, De Ferrari, Laura, Blasi, Francesco, Canevari, Rikki Frank, Canonica, Giorgio Walter, and Passalacqua, Giovanni

Published
2021
Full Text
View/download PDF

10. Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life

Author

Guarnieri, Gabriella, Patella, Vincenzo, Maria Pia, Foschino Barbaro, Carpagnano, Elisiana, Colle, Anna del, Scioscia, Giulia, Gerolamo, Pelaia, Paggiaro, Pierluigi, Latorre, Manuela, Puggioni, Francesca, Racca, Francesca, Favero, Elisabetta, Iannacone, Sandra, Savi, Eleonora, Montagni, Marcello, Camiciottoli, Gianna, Allegrini, Chiara, Spadaro, Giuseppe, Detoraki, Caterina, Galeone, Carla, Ruggiero, Patrizia, Yacoub, Monna Rita, Berti, Alvise, Colombo, Gisella, Scichilone, Nicola, Durante, Carmen, Costantino, Maria Teresa, Roncallo, Chiara, Braschi, Mariachiara, Blasi, Francesco, D'Adda, Alice, Ridolo, Erminia, Triggiani, Massimo, Parente, Roberta, Maria, D'Amato, Verrillo, Maria Vittoria, Cristina, Zappa Maria, Lilli, Marianna, Crimi, Nunzio, Bonavia, Marco, Corsico, Angelo Guido, Grosso, Amelia, Del Giacco, Stefano, Deidda, Margherita, Ricciardi, Luisa, Isola, Stefania, Cicero, Francesca, Amato, Giuliana, Vita, Federica, Spanevello, Antonio, Pignatti, Patrizia, Cherubino, Francesca, Visca, Dina, Aletti, Eleonora, Massimo Ricciardolo, Fabio Luigi, Anna Carriero, Vitina Maria, Bertolini, Francesca, Santus, Pierachille, Barlassina, Roberta, Airoldi, Andrea, Guida, Giuseppe, Eleonora, Nucera, Aruanno, Arianna, Rizzi, Angela, Caruso, Cristiano, Colantuono, Stefania, Arcolaci, Alessandra, Vianello, Andrea, Bianchi, Fulvia Chieco, Marchi, Maria Rita, Centanni, Stefano, Luraschi, Simone, Ruggeri, Silvia, Rinaldo, Rocco, Parazzini, Elena, Calabrese, Cecilia, Flora, Martina, Cosmi, Lorenzo, Di Pietro, Linda, Maggi, Enrico, Pini, Laura, Macchia, Luigi, Di Bona, Danilo, Richeldi, Luca, Condoluci, Carola, Fuso, Leonello, Bonini, Matteo, Farsi, Alessandro, Carli, Giulia, Montuschi, Paolo, Santini, Giuseppe, Conte, Maria Elisabetta, Turchet, Elisa, Barbetta, Carlo, Mazza, Francesco, D'Alo, Simona, Pucci, Stefano, Caiaffa, Maria Filomena, Minenna, Elena, D'Elia, Luciana, Pasculli, Carlo, Viviano, Vittorio, Tarsia, Paolo, Rolo, Joyce, Di Proietto, Mariacarmela, Lo Cicero, Salvatore, Bagnasco, Diego, Povero, Massimiliano, Pradelli, Lorenzo, Brussino, Luisa, Rolla, Giovanni, Caminati, Marco, Menzella, Francesco, Heffler, Enrico, Canonica, Giorgio Walter, Senna, Gianenrico, Milanese, Manlio, Lombardi, Carlo, Bucca, Caterina, Manfredi, Andrea, Canevari, Rikki Frank, and Passalacqua, Giovanni

Published
2021
Full Text
View/download PDF

11. Sustained Effectiveness of Benralizumab in Naïve and Biologics-Experienced Severe Eosinophilic Asthma Patients: Results from the ANANKE Study

Author

Cameli,Paolo, Aliani,Maria, Altieri,Elena, Bracciale,Pietro, Brussino,Luisa, Caiaffa,Maria Filomena, Canonica,Giorgio, Caruso,Cristiano, Centanni,Stefano, D'Amato,Maria, De Michele,Fausto, Del Giacco,Stefano, Di Marco,Fabiano, Pelaia,Girolamo, Rogliani,Paola, Romagnoli,Micaela, Schino,Pietro, Schroeder,Jan Walter, Senna,Gianenrico, Vultaggio,Alessandra, Benci,Marco, Boarino,Silvia, Menzella,Francesco, Cameli,Paolo, Aliani,Maria, Altieri,Elena, Bracciale,Pietro, Brussino,Luisa, Caiaffa,Maria Filomena, Canonica,Giorgio, Caruso,Cristiano, Centanni,Stefano, D'Amato,Maria, De Michele,Fausto, Del Giacco,Stefano, Di Marco,Fabiano, Pelaia,Girolamo, Rogliani,Paola, Romagnoli,Micaela, Schino,Pietro, Schroeder,Jan Walter, Senna,Gianenrico, Vultaggio,Alessandra, Benci,Marco, Boarino,Silvia, and Menzella,Francesco

Abstract

Paolo Cameli,1 Maria Aliani,2 Elena Altieri,3 Pietro Bracciale,4 Luisa Brussino,5 Maria Filomena Caiaffa,6 Giorgio Walter Canonica,7,8 Cristiano Caruso,9 Stefano Centanni,10 Maria D’Amato,11 Fausto De Michele,12 Stefano Del Giacco,13 Fabiano Di Marco,14 Girolamo Pelaia,15 Paola Rogliani,16,17 Micaela Romagnoli,18 Pietro Schino,19 Jan Walter Schroeder,20 Gianenrico Senna,21 Alessandra Vultaggio,22 Marco Benci,23 Silvia Boarino,24 Francesco Menzella25 1Respiratory Diseases Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy; 2UO Pneumologia e Pneumologia Riabilitativa, ICS Maugeri, IRCCS Bari, Bari, Italy; 3Reparto di Pneumologia, P.O. Garbagnate Milanese, Garbagnate Milanese (MI), Italy; 4Reparto di Pneumologia, Ospedale Ostuni, Ostuni (BR), Italy; 5Dipartimento di Scienze Mediche, Università degli Studi di Torino; SCDU Immunologia e Allergologia, AO Ordine Mauriziano Umberto I, Torino, Italy; 6Cattedra e Scuola di Allergologia e Immunologia Clinica, Dipartimento di Scienze Mediche, Università di Foggia, Foggia, Italy; 7Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy; 8Personalized Medicine Center: Asthma and Allergology, Humanitas Research Hospital, Rozzano (MI), Italy; 9Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico A. Gemelli, IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy; 10Respiratory Unit ASST Santi Paolo e Carlo, Department of Health Sciences Universita’ degli Studi di Milano, Milano, Italy; 11UOSD Malattie Respiratorie “Federico II”, Ospedale Monaldi, AO Dei Colli, Napoli, Italy; 12UOC Pneumologia e Fisiopatologia Respiratoria, AORN A. Cardarelli, Napoli, Italy; 13Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy; 14Department of Health Sciences, Università Degli Studi Di Milano, Pneumologia, ASST Papa Giovanni XXIII, Bergamo, Italy; 15Dipartimento di Scienze della Salute, Università Magna Graecia, C

Published
2024

12. Safety and treatment compliance of subcutaneous immunotherapy: A 30-year retrospective study

Author

Bariletto, Giuseppe, Carbonara, Annamaria, Cataldo, Vito, Damiani, Elisabetta, Di Leo, Elisabetta, Fiorino, Irene, Kourtis, Georgios, Laudadio, Valentina, Loconte, Filomena, Lotti, Anita, Mastromarco, Enza, Nenna, Saverio, Nico, Andrea, Pietrafesa, Maria, Rucco, Anna Simona, Strada, Silvana, Di Bona, Danilo, Magistà, Stefania, Masciopinto, Lucia, Lovecchio, Antonella, Loiodice, Roberto, Bilancia, Massimo, Albanesi, Marcello, Caiaffa, Maria Filomena, Nettis, Eustachio, and Macchia, Luigi

Published
2020
Full Text
View/download PDF

13. Features of severe asthma response to anti-IL5/IL5r therapies: identikit of clinical remission

Author

Carpagnano, Giovanna Elisiana, primary, Portacci, Andrea, additional, Nolasco, Santi, additional, Detoraki, Aikaterini, additional, Vatrella, Alessandro, additional, Calabrese, Cecilia, additional, Pelaia, Corrado, additional, Montagnolo, Francesca, additional, Scioscia, Giulia, additional, Valenti, Giuseppe, additional, D’Amato, Maria, additional, Caiaffa, Maria Filomena, additional, Triggiani, Massimo, additional, Scichilone, Nicola, additional, and Crimi, Claudia, additional

Published
2024
Full Text
View/download PDF

14. Real-world effectiveness and characteristics of Super-Responders to Mepolizumab and Benralizumab in severe eosinophilic asthma and EGPA

Author

Portacci, Andrea, primary, Campisi, Raffaele, additional, Buonamico, Enrico, additional, Nolasco, Santi, additional, Pelaia, Corrado, additional, Crimi, Nunzio, additional, Benfante, Alida, additional, Triggiani, Massimo, additional, Spadaro, Giuseppe, additional, Caiaffa, Maria Filomena, additional, Scioscia, Giulia, additional, Detoraki, Aikaterini, additional, Valenti, Giuseppe, additional, Papia, Francesco, additional, Tomasello, Alessandra, additional, Scichilone, Nicola, additional, Pelaia, Girolamo, additional, Crimi, Claudia, additional, and Carpagnano, Giovanna Elisiana, additional

Published
2023
Full Text
View/download PDF

15. Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps

Author

Pelaia, Corrado, primary, Benfante, Alida, additional, Busceti, Maria Teresa, additional, Caiaffa, Maria Filomena, additional, Campisi, Raffaele, additional, Carpagnano, Giovanna Elisiana, additional, Crimi, Nunzio, additional, D’Amato, Maria, additional, Foschino Barbaro, Maria Pia, additional, Maglio, Angelantonio, additional, Minenna, Elena, additional, Nolasco, Santi, additional, Paglino, Giuseppe, additional, Papia, Francesco, additional, Pelaia, Girolamo, additional, Portacci, Andrea, additional, Ricciardi, Luisa, additional, Scichilone, Nicola, additional, Scioscia, Giulia, additional, Triggiani, Massimo, additional, Valenti, Giuseppe, additional, Vatrella, Alessandro, additional, and Crimi, Claudia, additional

Published
2023
Full Text
View/download PDF

16. Real-world characteristics of “super-responders” to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis

Author

Portacci, Andrea, primary, Campisi, Raffaele, additional, Buonamico, Enrico, additional, Nolasco, Santi, additional, Pelaia, Corrado, additional, Crimi, Nunzio, additional, Benfante, Alida, additional, Triggiani, Massimo, additional, Spadaro, Giuseppe, additional, Caiaffa, Maria Filomena, additional, Scioscia, Giulia, additional, Detoraki, Aikaterini, additional, Valenti, Giuseppe, additional, Papia, Francesco, additional, Tomasello, Alessandra, additional, Scichilone, Nicola, additional, Pelaia, Girolamo, additional, Crimi, Claudia, additional, and Carpagnano, Giovanna Elisiana, additional

Published
2023
Full Text
View/download PDF

17. Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study

Author

Nolasco, Santi, primary, Portacci, Andrea, additional, Campisi, Raffaele, additional, Buonamico, Enrico, additional, Pelaia, Corrado, additional, Benfante, Alida, additional, Triggiani, Massimo, additional, Spadaro, Giuseppe, additional, Caiaffa, Maria Filomena, additional, Scioscia, Giulia, additional, Detoraki, Aikaterini, additional, Valenti, Giuseppe, additional, Papia, Francesco, additional, Tomasello, Alessandra, additional, Crimi, Nunzio, additional, Scichilone, Nicola, additional, Pelaia, Girolamo, additional, Carpagnano, Giovanna Elisiana, additional, and Crimi, Claudia, additional

Published
2023
Full Text
View/download PDF

18. Benralizumab in Patients with Severe Eosinophilic Asthma: A Multicentre Real-Life Experience

Author

Scioscia, Giulia, primary, Tondo, Pasquale, additional, Nolasco, Santi, additional, Pelaia, Corrado, additional, Carpagnano, Giovanna Elisiana, additional, Caiaffa, Maria Filomena, additional, Valenti, Giuseppe, additional, Maglio, Angelantonio, additional, Papia, Francesco, additional, Triggiani, Massimo, additional, Crimi, Nunzio, additional, Pelaia, Girolamo, additional, Vatrella, Alessandro, additional, Foschino Barbaro, Maria Pia, additional, and Crimi, Claudia, additional

Published
2023
Full Text
View/download PDF

22. Additional file 3 of Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study

Author

Vultaggio, Alessandra, Aliani, Maria, Altieri, Elena, Bracciale, Pietro, Brussino, Luisa, Caiaffa, Maria Filomena, Cameli, Paolo, Canonica, Giorgio Walter, Caruso, Cristiano, Centanni, Stefano, D’Amato, Maria, De Michele, Fausto, Del Giacco, Stefano, Di Marco, Fabiano, Menzella, Francesco, Pelaia, Girolamo, Rogliani, Paola, Romagnoli, Micaela, Schino, Pietro, Senna, Gianenrico, Benci, Marco, Boarino, Silvia, and Schroeder, Jan Walter

Abstract

Additional file 3: Table S3. Asthma-related healthcare resource utilization during benralizumab treatment. Data are expressed as mean ± SD.

Published
2023
Full Text
View/download PDF

23. Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps

Author

Pelaia, Corrado, Benfante, Alida, Busceti, Maria Teresa, Caiaffa, Maria Filomena, Campisi, Raffaele, Carpagnano, Giovanna Elisiana, Crimi, Nunzio, D’Amato, Maria, Foschino Barbaro, Maria Pia, Maglio, Angelantonio, Minenna, Elena, Nolasco, Santi, Paglino, Giuseppe, Papia, Francesco, Pelaia, Girolamo, Portacci, Andrea, Ricciardi, Luisa, Scichilone, Nicola, Scioscia, Giulia, Triggiani, Massimo, Valenti, Giuseppe, Vatrella, Alessandro, and Crimi, Claudia

Subjects
Immunology, Immunology and Allergy
Abstract

BackgroundThe efficacy of dupilumab as biological treatment of severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) depends on its ability to inhibit the pathophysiologic mechanisms involved in type 2 inflammation.ObjectiveTo assess in a large sample of subjects with severe asthma, the therapeutic impact of dupilumab in real-life, with regard to positive or negative skin prick test (SPT) and CRSwNP presence or absence.MethodsClinical, functional, and laboratory parameters were measured at baseline and 24 weeks after the first dupilumab administration. Moreover, a comparative evaluation was carried out in relation to the presence or absence of SPT positivity and CRSwNP.ResultsAmong the 127 recruited patients with severe asthma, 90 had positive SPT, while 78 reported CRSwNP. Compared with the 6 months preceding the first dupilumab injection, asthma exacerbations decreased from 4.0 (2.0-5.0) to 0.0 (0.0-0.0) (p < 0.0001), as well as the daily prednisone intake fell from 12.50 mg (0.00-25.00) to 0.00 mg (0.00-0.00) (p < 0.0001). In the same period, asthma control test (ACT) score increased from 14 (10-18) to 22 (20-24) (p < 0.0001), and sino-nasal outcome test (SNOT-22) score dropped from 55.84 ± 20.32 to 19.76 ± 12.76 (p < 0.0001). Moreover, we observed relevant increases in forced expiratory volume in one second (FEV1) from the baseline value of 2.13 L (1.62-2.81) to 2.39 L (1.89-3.06) (p < 0.0001). Fractional exhaled nitric oxide (FeNO) values decreased from 27.0 ppb (18.0-37.5) to 13.0 ppb (5.0-20.0) (p < 0.0001). These improvements were quite similar in subgroups of patients characterized by SPT negativity or positivity, and CRSwNP absence or presence. No statistically significant correlations were detected between serum IgE levels, baseline blood eosinophils or FeNO levels and dupilumab-induced changes, with the exception of FEV1 increase, which was shown to be positively correlated with FeNO values (r = 0.3147; p < 0.01).ConclusionOur results consolidate the strategic position of dupilumab in its role as an excellent therapeutic option currently available within the context of modern biological treatments of severe asthma and CRSwNP, frequently driven by type 2 airway inflammation.

Published
2023

24. Additional file 4 of Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study

Author

Vultaggio, Alessandra, Aliani, Maria, Altieri, Elena, Bracciale, Pietro, Brussino, Luisa, Caiaffa, Maria Filomena, Cameli, Paolo, Canonica, Giorgio Walter, Caruso, Cristiano, Centanni, Stefano, D’Amato, Maria, De Michele, Fausto, Del Giacco, Stefano, Di Marco, Fabiano, Menzella, Francesco, Pelaia, Girolamo, Rogliani, Paola, Romagnoli, Micaela, Schino, Pietro, Senna, Gianenrico, Benci, Marco, Boarino, Silvia, and Schroeder, Jan Walter

Abstract

Additional file 4: Table S4. Patients achieving MCID in ACT total score during benralizumab treatment. Data are reported as number and percentage of patients achieving MCID.

Published
2023
Full Text
View/download PDF

25. Additional file 1 of Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study

Author

Vultaggio, Alessandra, Aliani, Maria, Altieri, Elena, Bracciale, Pietro, Brussino, Luisa, Caiaffa, Maria Filomena, Cameli, Paolo, Canonica, Giorgio Walter, Caruso, Cristiano, Centanni, Stefano, D’Amato, Maria, De Michele, Fausto, Del Giacco, Stefano, Di Marco, Fabiano, Menzella, Francesco, Pelaia, Girolamo, Rogliani, Paola, Romagnoli, Micaela, Schino, Pietro, Senna, Gianenrico, Benci, Marco, Boarino, Silvia, and Schroeder, Jan Walter

Abstract

Additional file 1: Table S1. Patients disposition. Data are expressed as N. Percentages computed over the total number of enrolled patients. Percentages computed out of the number of eligible patients.

Published
2023
Full Text
View/download PDF

26. Additional file 5 of Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study

Author

Vultaggio, Alessandra, Aliani, Maria, Altieri, Elena, Bracciale, Pietro, Brussino, Luisa, Caiaffa, Maria Filomena, Cameli, Paolo, Canonica, Giorgio Walter, Caruso, Cristiano, Centanni, Stefano, D’Amato, Maria, De Michele, Fausto, Del Giacco, Stefano, Di Marco, Fabiano, Menzella, Francesco, Pelaia, Girolamo, Rogliani, Paola, Romagnoli, Micaela, Schino, Pietro, Senna, Gianenrico, Benci, Marco, Boarino, Silvia, and Schroeder, Jan Walter

Abstract

Additional file 5: Table S5. Socio-demographic, clinical and laboratory characteristics, data on prior asthma medication, exacerbations, lung function, ACT score of naïve and bio-experienced patients, collected before initiating benralizumab treatment. Data were collected at the index date or during the 12 months prior to the index date and are expressed as N, mean ± SD, or median. Unless otherwise stated, data are related to N = 124 naïve patients and N = 38 bio-experienced patients. Data are expressed as N, mean ± SD, or median. Unless otherwise stated, the evaluable population included 124 naïve patients and N = 38 bio-experienced patients.

Published
2023
Full Text
View/download PDF

27. Additional file 2 of Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study

Author

Vultaggio, Alessandra, Aliani, Maria, Altieri, Elena, Bracciale, Pietro, Brussino, Luisa, Caiaffa, Maria Filomena, Cameli, Paolo, Canonica, Giorgio Walter, Caruso, Cristiano, Centanni, Stefano, D’Amato, Maria, De Michele, Fausto, Del Giacco, Stefano, Di Marco, Fabiano, Menzella, Francesco, Pelaia, Girolamo, Rogliani, Paola, Romagnoli, Micaela, Schino, Pietro, Senna, Gianenrico, Benci, Marco, Boarino, Silvia, and Schroeder, Jan Walter

Abstract

Additional file 2: Table S2. Additional information related to maintenance asthma treatments, positivity to perennial allergens, comorbidities and OCS-related conditions collected before initiating benralizumab treatment. Data were collected at the index date or during the 12 months prior to the index date and are expressed as N, mean ± SD, or median. Unless otherwise stated, the evaluable population included 162 patients.

Published
2023
Full Text
View/download PDF

28. Switching from one biologic to benralizumab in patients with severe eosinophilic asthma: An ANANKE study post hoc analysis

Author

Caruso, Cristiano, Cameli, Paolo, Altieri, Elena, Aliani, Maria, Bracciale, Pietro, Brussino, Luisa, Caiaffa, Maria Filomena, Canonica, Giorgio Walter, Centanni, Stefano, D'Amato, Maria, Del Giacco, Stefano, De Michele, Fausto, Pastorello, Elide Anna, Pelaia, Girolamo, Rogliani, Paola, Romagnoli, Micaela, Schino, Pietro, Caminati, Marco, Vultaggio, Alessandra, Zullo, Alessandro, Rizzoli, Sara, Boarino, Silvia, Vitiello, Gianfranco, Menzella, Francesco, and Di Marco, Fabiano

Subjects
benralizumab, Settore MED/10, biologics, observational, severe eosinophilic asthma, switch, General Medicine
Abstract

BackgroundSevere asthma is a heterogeneous inflammatory disease driven by eosinophilic inflammation in the majority of cases. Despite biologic therapy patients may still be sub-optimally controlled, and the choice of the best biologic is a matter of debate. Indeed, switching between biologics is common, but no official guidelines are available and real-world data are limited.Materials and methodsIn this post hoc analysis of the Italian, multi-center, observational, retrospective study, ANANKE. Patients with severe eosinophilic asthma treated with benralizumab were divided in two groups based on history of previous biologic therapy (biologic-experienced [suboptimal response] vs naïve). Baseline clinical and laboratory characteristics were collected in the 12 months prior to benralizumab treatment. Change over time in blood eosinophils, annualized exacerbation rate (AER), asthma control (ACT), lung function and oral corticosteroid (OCS) use following benralizumab initiation were collected in the two groups.ResultsA total of 147 biologic-naïve and 58 biologic-experienced (34 omalizumab, 19 mepolizumab, and 5 omalizumab-mepolizumab) patients were enrolled. Biologic-experienced patients were more likely to be atopic and have a higher AER despite more frequent OCS use. Similar reductions in AER (>90% in both groups), OCS use (≥49% reduction in dosage and ≥41% able to eliminate OCS), ACT improvement (≥7 points gained in 48 weeks) and lung function (≥300 mL of FEV1 improvement in 48 weeks) were observed after benralizumab introduction within the two groups. There were no registered discontinuations of benralizumab for safety reasons.ConclusionIn this post hoc analysis, patients who were switched to benralizumab because of suboptimal control with a previous biologic therapy were more likely to be atopic and more often treated with omalizumab. Benralizumab is effective in both naïve patients and those previously treated with a biologic.

Published
2022

30. Clinical Features and Efficacy of Benralizumab in Patients with Blood Eosinophil Count Between 300 and 450 Cells/mm3: A Post Hoc Analysis from the ANANKE Study

Author

Senna, Gianenrico, primary, Aliani, Maria, additional, Altieri, Elena, additional, Bracciale, Pietro, additional, Brussino, Luisa, additional, Caiaffa, Maria Filomena, additional, Cameli, Paolo, additional, Canonica, Giorgio Walter, additional, Caruso, Cristiano, additional, D'Amato, Maria, additional, De Michele, Fausto, additional, Del Giacco, Stefano, additional, Di Marco, Fabiano, additional, Menzella, Francesco, additional, Pelaia, Girolamo, additional, Rogliani, Paola, additional, Romagnoli, Micaela, additional, Schino, Pietro, additional, Schroeder, Jan Walter, additional, Vultaggio, Alessandra, additional, Rizzoli, Sara, additional, Zullo, Alessandro, additional, Boarino, Silvia, additional, Palmisano, Marilena, additional, Rossi, Alessandra, additional, Vitiello, Gianfranco, additional, and Centanni, Stefano, additional

Published
2022
Full Text
View/download PDF

32. Benralizumab in Patients With Severe Eosinophilic Asthma With and Without Chronic Rhinosinusitis With Nasal Polyps: An ANANKE Study post-hoc Analysis

Author

D'Amato, Maria, Menzella, Francesco, Altieri, Elena, Bargagli, Elena, Bracciale, Pietro, Brussino, Luisa, Caiaffa, Maria Filomena, Canonica, Giorgio Walter, Caruso, Cristiano, Centanni, Stefano, De Michele, Fausto, Di Marco, Fabiano, Pastorello, Elide Anna, Pelaia, Girolamo, Rogliani, Paola, Romagnoli, Micaela, Schino, Pietro, Senna, Gianenrico, Vultaggio, Alessandra, Ori, Alessandra, Simoni, Lucia, Boarino, Silvia, Vitiello, Gianfranco, Aliani, Maria, and Del Giacco, Stefano

Subjects
benralizumab, biologics, chronic rhinosinusitis with nasal polyps, observational, severe eosinophilic asthma, Settore MED/10
Abstract

BackgroundSevere eosinophilic asthma (SEA) in the presence of chronic rhinosinusitis with nasal polyps (CRSwNP) indicates the presence of a more extensive eosinophilic inflammation. Post-hoc analyses from a pivotal clinical trial have demonstrated the enhanced efficacy of benralizumab on asthma outcomes in patients with CRSwNP as a comorbidity.MethodsThis is a post-hoc analysis from the Italian multi-center observational retrospective ANANKE study. Patients were divided into two groups based on self-reported CRSwNP. Baseline clinical and laboratory features in the 12 months prior to benralizumab prescription were collected. Data of change over time of blood eosinophils, annualized exacerbations rates (AER), asthma control, lung function, oral corticosteroids (OCS) use, and benralizumab discontinuation were collected during the observation period.ResultsAt baseline, the 110 patients with CRSwNP were less frequently female (50.9% vs 74.2%) and obese (9.1% vs. 22.6%) with higher eosinophils (605 vs. 500 cells/mm3) and OCS use when compared to patients without CRSwNP. Similar reductions of AER were seen (-95.8% vs. −91.5% for any exacerbation and −99.1% vs. −92.2% for severe exacerbations in patients with and without CRSwNP, respectively). During benralizumab treatment, comorbid SEA+CRSwNP was associated with a lower risk of any exacerbation (p = 0.0017) and severe exacerbations (p = 0.025). After a mean ± SD exposure of 10.3 ± 5.0 months, half of the SEA+CRSwNP patients eliminated OCS use. No discontinuation for safety reasons was recorded.ConclusionsThis study helped to confirm the baseline clinical features that distinguish patients with and without CRSwNP being prescribed benralizumab. Numerically enhanced OCS reduction and lower exacerbation risk were observed in patients with SEA and comorbid CRSwNP treated with benralizumab.

Published
2022

33. Clinical Features and Efficacy of Benralizumab in Patients with Blood Eosinophil Count Between 300 and 450 Cells/mm3: A Post Hoc Analysis from the ANANKE Study

Author

Senna,Gianenrico, Aliani,Maria, Altieri,Elena, Bracciale,Pietro, Brussino,Luisa, Caiaffa,Maria Filomena, Cameli,Paolo, Canonica,Giorgio Walter, Caruso,Cristiano, D'Amato,Maria, De Michele,Fausto, Del Giacco,Stefano, Di Marco,Fabiano, Menzella,Francesco, Pelaia,Girolamo, Rogliani,Paola, Romagnoli,Micaela, Schino,Pietro, Schroeder,Jan Walter, Vultaggio,Alessandra, Rizzoli,Sara, Zullo,Alessandro, Boarino,Silvia, Palmisano,Marilena, Rossi,Alessandra, Vitiello,Gianfranco, Centanni,Stefano, Senna,Gianenrico, Aliani,Maria, Altieri,Elena, Bracciale,Pietro, Brussino,Luisa, Caiaffa,Maria Filomena, Cameli,Paolo, Canonica,Giorgio Walter, Caruso,Cristiano, D'Amato,Maria, De Michele,Fausto, Del Giacco,Stefano, Di Marco,Fabiano, Menzella,Francesco, Pelaia,Girolamo, Rogliani,Paola, Romagnoli,Micaela, Schino,Pietro, Schroeder,Jan Walter, Vultaggio,Alessandra, Rizzoli,Sara, Zullo,Alessandro, Boarino,Silvia, Palmisano,Marilena, Rossi,Alessandra, Vitiello,Gianfranco, and Centanni,Stefano

Abstract

Gianenrico Senna,1,2 Maria Aliani,3 Elena Altieri,4 Pietro Bracciale,5 Luisa Brussino,6 Maria Filomena Caiaffa,7 Paolo Cameli,8 Giorgio Walter Canonica,9,10 Cristiano Caruso,11 Maria D’Amato,12 Fausto De Michele,13 Stefano Del Giacco,14 Fabiano Di Marco,15 Francesco Menzella,16 Girolamo Pelaia,17 Paola Rogliani,18,19 Micaela Romagnoli,20 Pietro Schino,21 Jan Walter Schroeder,22 Alessandra Vultaggio,23 Sara Rizzoli,24 Alessandro Zullo,24 Silvia Boarino,25 Marilena Palmisano,26 Alessandra Rossi,26 Gianfranco Vitiello,26 Stefano Centanni27 1Department of Medicine, University of Verona, Verona, Italy; 2Allergy Unit and Asthma Center, Verona University Hospital, Verona, Italy; 3UO Pneumologia e Pneumologia Riabilitativa, ICS Maugeri, IRCCS Bari, Bari, Italy; 4Reparto di Pneumologia, P.O., Garbagnate Milanese, Italy; 5Reparto di Pneumologia, Ospedale Ostuni, Ostuni, BR, Italy; 6Dipartimento di Scienze Mediche, SSDDU Allergologia e Immunologia Clinica, Università degli Studi di Torino, AO Ordine Mauriziano Umberto I, Torino, Italy; 7Cattedra e Scuola di Allergologia e Immunologia Clinica, Dipartimento di Scienze Mediche, Università di Foggia, Foggia, Italy; 8Respiratory Diseases and Lung Transplantation, Department of Medical and Surgical Sciences & Neurosciences, Siena University Hospital, Siena, Italy; 9Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, MI, Italy; 10Personalized Medicine Center: Asthma and Allergology, Humanitas Research Hospital, Rozzano, MI, Italy; 11Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico A. Gemelli, IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy; 12UOSD Malattie Respiratorie “Federico II”, Ospedale Monaldi, AO Dei Colli, Napoli, Italy; 13UOC Pneumologia e Fisiopatologia Respiratoria, AORN A. Cardarelli, Napoli, Italy; 14Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy; 15Department of Health Sciences, Università Degli Studi Di Milano

Published
2022

34. Benralizumab in Patients With Severe Eosinophilic Asthma With and Without Chronic Rhinosinusitis With Nasal Polyps: An ANANKE Study post-hoc Analysis

Author

D'Amato, Maria, primary, Menzella, Francesco, additional, Altieri, Elena, additional, Bargagli, Elena, additional, Bracciale, Pietro, additional, Brussino, Luisa, additional, Caiaffa, Maria Filomena, additional, Canonica, Giorgio Walter, additional, Caruso, Cristiano, additional, Centanni, Stefano, additional, De Michele, Fausto, additional, Di Marco, Fabiano, additional, Pastorello, Elide Anna, additional, Pelaia, Girolamo, additional, Rogliani, Paola, additional, Romagnoli, Micaela, additional, Schino, Pietro, additional, Senna, Gianenrico, additional, Vultaggio, Alessandra, additional, Ori, Alessandra, additional, Simoni, Lucia, additional, Boarino, Silvia, additional, Vitiello, Gianfranco, additional, Aliani, Maria, additional, and Del Giacco, Stefano, additional

Published
2022
Full Text
View/download PDF

35. Additional file 5 of ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study

Author

Menzella, Francesco, Bargagli, Elena, Aliani, Maria, Bracciale, Pietro, Brussino, Luisa, Caiaffa, Maria Filomena, Caruso, Cristiano, Centanni, Stefano, D���Amato, Maria, Del Giacco, Stefano, De Michele, Fausto, Di Marco, Fabiano, Pastorello, Elide Anna, Pelaia, Girolamo, Rogliani, Paola, Romagnoli, Micaela, Schino, Pietro, Senna, Gianenrico, Vultaggio, Alessandra, Simoni, Lucia, Ori, Alessandra, Boarino, Silvia, Vitiello, Gianfranco, Altieri, Elena, and Canonica, Giorgio Walter

Abstract

Additional file 5: Table S1. Patient characteristics recorded before the start of benralizumab therapy. Data are N (%), mean��SD, or median (IQR). Unless otherwise specified, the evaluable populations included 85 allergic and 120 non-allergic patients.

Published
2022
Full Text
View/download PDF

36. Additional file 1 of Novel approach to idursulfase and laronidase desensitization in type 2 and type 1 S mucopolysaccharidosis (MPS)

Author

Spataro, Federico, Viggiani, Fabio, Macchia, Domenico Giorgio, Rollo, Valentina, Tummolo, Albina, Suppressa, Patrizia, Sabba’, Carlo, Rossi, Maria Pia, Giliberti, Lucia, Satriano, Francesco, Nettis, Eustachio, Di Bona, Danilo, Caiaffa, Maria Filomena, Fischetto, Rita, and Macchia, Luigi

Abstract

Supplementary Material 1

Published
2022
Full Text
View/download PDF

37. Additional file 6 of ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study

Author

Menzella, Francesco, Bargagli, Elena, Aliani, Maria, Bracciale, Pietro, Brussino, Luisa, Caiaffa, Maria Filomena, Caruso, Cristiano, Centanni, Stefano, D���Amato, Maria, Del Giacco, Stefano, De Michele, Fausto, Di Marco, Fabiano, Pastorello, Elide Anna, Pelaia, Girolamo, Rogliani, Paola, Romagnoli, Micaela, Schino, Pietro, Senna, Gianenrico, Vultaggio, Alessandra, Simoni, Lucia, Ori, Alessandra, Boarino, Silvia, Vitiello, Gianfranco, Altieri, Elena, and Canonica, Giorgio Walter

Abstract

Additional file 6: Table S2. Evaluable patients with data on OCS use at the index date and at enrolment are 14 for allergic and 30 for non-allergic subjects. OCS dose is indicated as a median (IQR).

Published
2022
Full Text
View/download PDF

39. Sustained drug-related reaction with eosinophilia and systemic symptoms (DRESS) triggered by low molecular weight heparins in COVID-19: management and precision diagnosis

Author

Minenna, Elena, primary, Chaoul, Nada, additional, Pia Rossi, Maria, additional, Giliberti, Lucia, additional, Albanesi, Marcello, additional, Nettis, Eustachio, additional, Foschino Barbaro, Maria Pia, additional, Bona, Danilo Di, additional, Caiaffa, Maria Filomena, additional, and Macchia, Luigi, additional

Published
2022
Full Text
View/download PDF

41. Severe asthma: One disease and multiple definitions

Author

Bagnasco, Diego, primary, Paggiaro, Pierluigi, additional, Latorre, Manuela, additional, Folli, Chiara, additional, Testino, Elisa, additional, Bassi, Arianna, additional, Milanese, Manlio, additional, Heffler, Enrico, additional, Manfredi, Andrea, additional, Riccio, Anna Maria, additional, De Ferrari, Laura, additional, Blasi, Francesco, additional, Canevari, Rikki Frank, additional, Canonica, Giorgio Walter, additional, Passalacqua, Giovanni, additional, Guarnieri, Gabriella, additional, Patella, Vincenzo, additional, Maria Pia, Foschino Barbaro, additional, Carpagnano, Giovanna Elisiana, additional, Colle, Anna del, additional, Scioscia, Giulia, additional, Gerolamo, Pelaia, additional, Puggioni, Francesca, additional, Racca, Francesca, additional, Favero, Elisabetta, additional, Iannacone, Sandra, additional, Savi, Eleonora, additional, Montagni, Marcello, additional, Camiciottoli, Gianna, additional, Allegrini, Chiara, additional, Lombardi, Carlo, additional, Spadaro, Giuseppe, additional, Detoraki, Caterina, additional, Menzella, Francesco, additional, Galeone, Carla, additional, Ruggiero, Patrizia, additional, Yacoub, Monna Rita, additional, Berti, Alvise, additional, Scichilone, Nicola, additional, Durante, Carmen, additional, Costantino, Maria Teresa, additional, Roncallo, Chiara, additional, Braschi, Mariachiara, additional, D’Adda, Alice, additional, Ridolo, Erminia, additional, Triggiani, Massimo, additional, Parente, Roberta, additional, Maria, D’Amato, additional, Verrillo, Maria Vittoria, additional, Rolla, Giovanni, additional, Brussino, Luisa, additional, Frazzetto, Agata Valentina, additional, Cristina, Zappa Maria, additional, Lilli, Marianna, additional, Crimi, Nunzio, additional, Bonavia, Marco, additional, Corsico, Angelo Guido, additional, Grosso, Amelia, additional, Del Giacco, Stefano, additional, Deidda, Margherita, additional, Ricciardi, Luisa, additional, Isola, Stefania, additional, Cicero, Francesca, additional, Amato, Giuliana, additional, Vita, Federica, additional, Spanevello, Antonio, additional, Pignatti, Patrizia, additional, Cherubino, Francesca, additional, Visca, Dina, additional, Massimo Ricciardolo, Fabio Luigi, additional, Anna Carriero, Vitina Maria, additional, Bertolini, Francesca, additional, Santus, Pierachille, additional, Barlassina, Roberta, additional, Airoldi, Andrea, additional, Guida, Giuseppe, additional, Eleonora, Nucera, additional, Aruanno, Arianna, additional, Rizzi, Angela, additional, Caruso, Cristiano, additional, Colantuono, Stefania, additional, Senna, Gianenrico, additional, Caminati, Marco, additional, Arcolaci, Alessandra, additional, Vianello, Andrea, additional, Bianchi, Fulvia Chieco, additional, Marchi, Maria Rita, additional, Centanni, Stefano, additional, Luraschi, Simone, additional, Ruggeri, Silvia, additional, Rinaldo, Rocco, additional, Parazzini, Elena, additional, Calabrese, Cecilia, additional, Flora, Martina, additional, Cosmi, Lorenzo, additional, Di Pietro, Linda, additional, Maggi, Enrico, additional, Pini, Laura, additional, Macchia, Luigi, additional, Di Bona, Danilo, additional, Richeldi, Luca, additional, Condoluci, Carola, additional, Fuso, Leonello, additional, Bonini, Matteo, additional, Farsi, Alessandro, additional, Carli, Giulia, additional, Montuschi, Paolo, additional, Santini, Giuseppe, additional, Conte, Maria Elisabetta, additional, Turchet, Elisa, additional, Barbetta, Carlo, additional, Mazza, Francesco, additional, D’Alo, Simona, additional, Pucci, Stefano, additional, Caiaffa, Maria Filomena, additional, Minenna, Elena, additional, D'Elia, Luciana, additional, Pasculli, Carlo, additional, Viviano, Vittorio, additional, Tarsia, Paolo, additional, Rolo, Joyce, additional, Di Proietto, Mariacarmela, additional, and Lo Cicero, Salvatore, additional

Published
2021
Full Text
View/download PDF

42. Effectiveness of benralizumab in severe eosinophilic asthma: Distinct sub‐phenotypes of response identified by cluster analysis

Author

Di Bona, Danilo, primary, Crimi, Claudia, additional, D’Uggento, Angela Maria, additional, Benfante, Alida, additional, Caiaffa, Maria Filomena, additional, Calabrese, Cecilia, additional, Campisi, Raffaele, additional, Carpagnano, Giovanna Elisiana, additional, Ciotta, Domenico, additional, D'Amato, Maria, additional, Pelaia, Corrado, additional, Pelaia, Girolamo, additional, Pellegrino, Simona, additional, Scichilone, Nicola, additional, Scioscia, Giulia, additional, Ribecco, Nunziata, additional, Spadaro, Giuseppe, additional, Valenti, Giuseppe, additional, Vatrella, Alessandro, additional, Crimi, Nunzio, additional, and Macchia, Luigi, additional

Published
2021
Full Text
View/download PDF

43. Clinical Features and Efficacy of Benralizumab in Patients with Blood Eosinophil Count Between 300 and 450 Cells/mm3: A Post Hoc Analysis from the ANANKE Study.

Author

Senna, Gianenrico, Aliani, Maria, Altieri, Elena, Bracciale, Pietro, Brussino, Luisa, Caiaffa, Maria Filomena, Cameli, Paolo, Canonica, Giorgio Walter, Caruso, Cristiano, D'Amato, Maria, De Michele, Fausto, Del Giacco, Stefano, Marco, Fabiano Di, Menzella, Francesco, Pelaia, Girolamo, Rogliani, Paola, Romagnoli, Micaela, Schino, Pietro, Schroeder, Jan Walter, and Vultaggio, Alessandra

Subjects
EOSINOPHILS, PATHOLOGICAL laboratories
Abstract

Purpose: Benralizumab effectively reduces severe eosinophilic asthma (SEA) exacerbations in patients with a wide range of baseline blood eosinophil count (BEC). Patients included in real-world studies are often characterized by high mean/median BEC, while patients with BEC close to 300 cells/mm3 are poorly represented. This post hoc analysis from the Italian study ANANKE aims to define the clinical features and corroborate the efficacy of benralizumab in real world in the BEC 300– 450 cells/mm3 subset of patients. Patients and Methods: Post hoc analysis of the Italian, multicenter, observational, retrospective real-life study ANANKE (NCT04272463). Baseline clinical and laboratory characteristics were collected in the 12 months prior to benralizumab treatment and presented for a BEC 300– 450 cells/mm3 subgroup of patients. Change over time of BEC, annualized exacerbation rate (AER), asthma control (ACT), lung function and oral corticosteroid (OCS) use at 16, 24 and 48 weeks after benralizumab introduction were collected. Results: A total of 164 patients were analyzed, 34 of whom with a BEC of 300– 450 cells/mm3. This subgroup was more likely to be female (64.7%), with lower rates of severe exacerbations at baseline when compared to the total population (0.69 vs 1.01). After 48 weeks of benralizumab treatment, the BEC 300– 450 subset showed similar reductions in AER (− 94.8% vs − 92.2%) and OCS use (median dose reduction of 100% in both groups), as well as improvement in ACT score (median scores 22.5 vs 22) and lung function (pre-BD FEV1: +200 mL vs +300 mL) when compared to the total population. No discontinuations for safety reasons were registered. Conclusion: At baseline, apart from lower severe exacerbation rate, the BEC 300– 450 cells/mm3 subset of patients is comparable to the total population prescribed with benralizumab. In this real-life study, benralizumab is as effective in BEC 300– 450 patients as in the total population. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

44. Mild/Moderate Asthma Network in Italy (MANI): a long-term observational study.

Author

Braido, Fulvio, Blasi, Francesco, Canonica, Giorgio Walter, Paggiaro, Pierluigi, Beghè, Bianca, Bonini, Matteo, Carpagnano, Giovanna Elisiana, Del Giacco, Stefano, Lavorini, Federico, Milanese, Manlio, Patella, Vincenzo, Santus, Pierachille, Contoli, Marco, Allegrini, Chiara, Baiardini, Ilaria, Bonzano, Laura, Caiaffa, Maria Filomena, Castelnuovo, Paolo, Corsico, Angelo Guido, and Cosmi, Lorenzo

Subjects
ASTHMA, ASTHMATICS, SCIENTIFIC observation, MEDICAL research, CLINICAL immunology, WHEEZE
Abstract

The prevalence of asthma in Italy is estimated to be around 4%; it affects approximately 2,000,000 citizens, and up to 80–90% of patients have mild-to-moderate asthma. Despite the clinical relevance of mild-to-moderate asthma, longitudinal observational data are very limited, including data on disease progression (worsening vs. improvement), the response to treatment, and prognosis. Studies are needed to develop long-term, observational, real-life research in large cohorts. The primary outcomes of this study will be based on prospective observation and the epidemiological evolution of mild and moderate asthma. Secondary outcomes will include patient-reported outcomes, treatments over time, disease-related functional and inflammatory patterns, and environmental and life-style influences. This study, called the Mild/Moderate Asthma Network of Italy (MANI), is a research initiative launched by the Italian Respiratory Society and the Italian Society of Allergology, Asthma and Clinical Immunology. MANI is a cluster-based, real world, cross-sectional, prospective, observational cohort study that includes 20,000 patients with mild-to-moderate asthma. (ClinicalTrials.gov Identifier: NCT04796844). Despite advances in asthma care, several research gaps remain to be addressed through clinical research. This study will add important new knowledge about long-term disease history, the transferability of clinical research results to daily practice, the efficacy of currently recommended strategies, and their impact on the burden and evolution of the disease. MANI: Mild/Moderate Asthma Network of Italy SANI: Severe Asthma Network Italy GINA: Global Initiative for Asthma SABA: short acting β2-agonists ICS: inhaled corticosteroids CRF: Case Report Form [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

45. Therapeutic Effects of Benralizumab Assessed in Patients with Severe Eosinophilic Asthma: Real-Life Evaluation Correlated with Allergic and Non-Allergic Phenotype Expression

Author

Pelaia,Corrado, Crimi,Claudia, Benfante,Alida, Caiaffa,Maria Filomena, Calabrese,Cecilia, Carpagnano,Giovanna Elisiana, Ciotta,Domenico, D'Amato,Maria, Macchia,Luigi, Nolasco,Santi, Pelaia,Girolamo, Pellegrino,Simona, Scichilone,Nicola, Scioscia,Giulia, Spadaro,Giuseppe, Valenti,Giuseppe, Vatrella,Alessandro, Crimi,Nunzio, Pelaia,Corrado, Crimi,Claudia, Benfante,Alida, Caiaffa,Maria Filomena, Calabrese,Cecilia, Carpagnano,Giovanna Elisiana, Ciotta,Domenico, D'Amato,Maria, Macchia,Luigi, Nolasco,Santi, Pelaia,Girolamo, Pellegrino,Simona, Scichilone,Nicola, Scioscia,Giulia, Spadaro,Giuseppe, Valenti,Giuseppe, Vatrella,Alessandro, and Crimi,Nunzio

Abstract

Corrado Pelaia,1 Claudia Crimi,2 Alida Benfante,3 Maria Filomena Caiaffa,4 Cecilia Calabrese,5 Giovanna Elisiana Carpagnano,6 Domenico Ciotta Jnr,7 Maria D’Amato,8 Luigi Macchia,9 Santi Nolasco,2 Girolamo Pelaia,1 Simona Pellegrino,7 Nicola Scichilone,3 Giulia Scioscia,10 Giuseppe Spadaro,11 Giuseppe Valenti,12 Alessandro Vatrella,7 Nunzio Crimi2 1Department of Health Sciences, University “Magna Graecia” of Catanzaro, Catanzaro, Italy; 2Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy; 3Department of Biomedicine and Internal and Specialistic Medicine, University of Palermo, Palermo, Italy; 4Allergology and Clinical Immunology Unit, University of Foggia, Foggia, Italy; 5Department of Translational Medical Sciences, University of Campania “Luigi Vanvitelli”, Foggia, Italy; 6Department of Basic Medical Sciences, Neuroscience and Sense Organs, Section of Respiratory Disease, University “Aldo Moro” of Bari, Bari, Italy; 7Department of Medicine, Surgery and Dentistry, University of Salerno, Salerno, Italy; 8Division of Pneumology, “V. Monaldi” University Hospital, Naples, Italy; 9Allergology and Clinical Immunology Unit, University “Aldo Moro” of Bari, Bari, Italy; 10Department of Medical and Surgical Sciences, Institute of Respiratory Diseases, University of Foggia, Foggia, Italy; 11Allergology and Immunology Unit, University “Federico II” of Naples, Naples, Italy; 12Allergology and Pulmonology Unit, Provincial Outpatient Center of Palermo, Palermo, ItalyCorrespondence: Corrado PelaiaDepartment of Health Sciences, University “Magna Graecia” of Catanzaro, Catanzaro, ItalyTel + 39 0961 3647007Email pelaia.corrado@gmail.comBackground: Benralizumab can be utilized as add-on biological treatment of severe eosinophilic asthma. However, so far only a few real-life studies have been published

Published
2021

46. Sustained Drug-related Reaction With Eosinophilia and Systemic Symptoms (DRESS) Triggered by Low Molecular Weight Heparins in COVID-19: Management and Precision Diagnosis.

Author

Minenna, Elena, primary, Chaoul, Nada, additional, Rossi, Maria Pia, additional, Giliberti, Lucia, additional, Albanesi, Marcello, additional, Nettis, Eustachio, additional, Barbaro, Maria Pia Foschino, additional, Bona, Danilo Di, additional, Caiaffa, Maria Filomena, additional, and Macchia, Luigi, additional

Published
2021
Full Text
View/download PDF

47. Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life

Author

Bagnasco, Diego, primary, Povero, Massimiliano, additional, Pradelli, Lorenzo, additional, Brussino, Luisa, additional, Rolla, Giovanni, additional, Caminati, Marco, additional, Menzella, Francesco, additional, Heffler, Enrico, additional, Canonica, Giorgio Walter, additional, Paggiaro, Pierluigi, additional, Senna, Gianenrico, additional, Milanese, Manlio, additional, Lombardi, Carlo, additional, Bucca, Caterina, additional, Manfredi, Andrea, additional, Canevari, Rikki Frank, additional, Passalacqua, Giovanni, additional, Guarnieri, Gabriella, additional, Patella, Vincenzo, additional, Maria Pia, Foschino Barbaro, additional, Carpagnano, Elisiana, additional, Colle, Anna del, additional, Scioscia, Giulia, additional, Gerolamo, Pelaia, additional, Latorre, Manuela, additional, Puggioni, Francesca, additional, Racca, Francesca, additional, Favero, Elisabetta, additional, Iannacone, Sandra, additional, Savi, Eleonora, additional, Montagni, Marcello, additional, Camiciottoli, Gianna, additional, Allegrini, Chiara, additional, Spadaro, Giuseppe, additional, Detoraki, Caterina, additional, Galeone, Carla, additional, Ruggiero, Patrizia, additional, Yacoub, Monna Rita, additional, Berti, Alvise, additional, Colombo, Gisella, additional, Scichilone, Nicola, additional, Durante, Carmen, additional, Costantino, Maria Teresa, additional, Roncallo, Chiara, additional, Braschi, Mariachiara, additional, Blasi, Francesco, additional, D'Adda, Alice, additional, Ridolo, Erminia, additional, Triggiani, Massimo, additional, Parente, Roberta, additional, Maria, D'Amato, additional, Verrillo, Maria Vittoria, additional, Cristina, Zappa Maria, additional, Lilli, Marianna, additional, Crimi, Nunzio, additional, Bonavia, Marco, additional, Corsico, Angelo Guido, additional, Grosso, Amelia, additional, Del Giacco, Stefano, additional, Deidda, Margherita, additional, Ricciardi, Luisa, additional, Isola, Stefania, additional, Cicero, Francesca, additional, Amato, Giuliana, additional, Vita, Federica, additional, Spanevello, Antonio, additional, Pignatti, Patrizia, additional, Cherubino, Francesca, additional, Visca, Dina, additional, Aletti, Eleonora, additional, Massimo Ricciardolo, Fabio Luigi, additional, Anna Carriero, Vitina Maria, additional, Bertolini, Francesca, additional, Santus, Pierachille, additional, Barlassina, Roberta, additional, Airoldi, Andrea, additional, Guida, Giuseppe, additional, Eleonora, Nucera, additional, Aruanno, Arianna, additional, Rizzi, Angela, additional, Caruso, Cristiano, additional, Colantuono, Stefania, additional, Arcolaci, Alessandra, additional, Vianello, Andrea, additional, Bianchi, Fulvia Chieco, additional, Marchi, Maria Rita, additional, Centanni, Stefano, additional, Luraschi, Simone, additional, Ruggeri, Silvia, additional, Rinaldo, Rocco, additional, Parazzini, Elena, additional, Calabrese, Cecilia, additional, Flora, Martina, additional, Cosmi, Lorenzo, additional, Di Pietro, Linda, additional, Maggi, Enrico, additional, Pini, Laura, additional, Macchia, Luigi, additional, Di Bona, Danilo, additional, Richeldi, Luca, additional, Condoluci, Carola, additional, Fuso, Leonello, additional, Bonini, Matteo, additional, Farsi, Alessandro, additional, Carli, Giulia, additional, Montuschi, Paolo, additional, Santini, Giuseppe, additional, Conte, Maria Elisabetta, additional, Turchet, Elisa, additional, Barbetta, Carlo, additional, Mazza, Francesco, additional, D'Alo, Simona, additional, Pucci, Stefano, additional, Caiaffa, Maria Filomena, additional, Minenna, Elena, additional, D'Elia, Luciana, additional, Pasculli, Carlo, additional, Viviano, Vittorio, additional, Tarsia, Paolo, additional, Rolo, Joyce, additional, Di Proietto, Mariacarmela, additional, and Lo Cicero, Salvatore, additional

Published
2021
Full Text
View/download PDF

48. Therapeutic Effects of Benralizumab Assessed in Patients with Severe Eosinophilic Asthma: Real-Life Evaluation Correlated with Allergic and Non-Allergic Phenotype Expression

Author

Pelaia, Corrado, primary, Crimi, Claudia, additional, Benfante, Alida, additional, Caiaffa, Maria Filomena, additional, Calabrese, Cecilia, additional, Carpagnano, Giovanna Elisiana, additional, Ciotta, Domenico, additional, D'Amato, Maria, additional, Macchia, Luigi, additional, Nolasco, Santi, additional, Pelaia, Girolamo, additional, Pellegrino, Simona, additional, Scichilone, Nicola, additional, Scioscia, Giulia, additional, Spadaro, Giuseppe, additional, Valenti, Giuseppe, additional, Vatrella, Alessandro, additional, and Crimi, Nunzio, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results